bioMérieux SA engages in the provision of in vitro diagnostic solutions, which determine the source of disease and contamination. The company is headquartered in Craponne, Auvergne-Rhone-Alpes and currently employs 14,754 full-time employees. The company went IPO on 2004-06-07. The firm designs, develops, manufactures and sells systems used in clinical applications, such as for the diagnosis of tuberculosis, respiratory infections, among others and industrial applications, such as for the analysis of industrial or environmental samples. The firm also provides its customers with related services for the installation and maintenance of instruments, and training for product users. BioMerieux SA operates through its numerous subsidiaries in various countires, including bioMerieux Deutschland GmbH, bioMerieux Austria GmbH, Advencis, bioMerieux Benelux SA/NV, as well as BioFire Diagnostics Inc., chromID CARBA SMART and new bi-plate Petri dish.
Follow-Up Questions
Quelle est la performance du prix de l'action BMXMF ?
Le prix actuel de BMXMF est de $134.24, il a decreased de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Biomerieux SA ?
Biomerieux SA appartient à l'industrie Health Care et le secteur est Health Care
Quelle est la capitalisation boursière de Biomerieux SA ?
La capitalisation boursière actuelle de Biomerieux SA est de $15.8B
Est-ce que Biomerieux SA est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 16 analystes ont établi des notations d'analystes pour Biomerieux SA, y compris 2 achat fort, 9 achat, 6 maintien, 1 vente et 2 vente forte
